查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951856

腫瘤精準醫療市場分析及預測（至2035年）：類型、產品類型、服務、技術、應用、最終用戶、組件、實施類型、解決方案與階段

Oncology Precision Medicine Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Deployment, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 359 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

腫瘤精準醫療市場預計將從2024年的613億美元成長到2034年的1,591億美元，複合年成長率約為9.4%。腫瘤精準醫療市場涵蓋了針對個人基因譜量身定做的標靶治療和診斷技術，旨在提高治療效果並減少副作用。基因組學、生物資訊學和個人化醫療的進步推動了該市場的發展，使得癌症突變的精準識別成為可能。癌症發病率的上升和對個人化治療的需求正在推動生物標記發現和伴隨診斷技術的創新，從而促進市場成長。

癌症精準醫療市場正經歷強勁成長，這主要得益於個人化治療方法和分子診斷技術的進步。診斷領域是推動市場發展的關鍵力量，其中次世代定序和液態生物檢體技術在癌症的早期精準檢測中發揮著至關重要的作用。特別是次世代定序，因其全面的基因組分析能力而備受關注。治療藥物領域也緊隨其後，標靶治療和免疫療法正在改變癌症治療模式。在治療藥物領域，標靶治療是表現最佳的細分市場，它提供的個人化治療方案能夠改善患者的治療效果。免疫療法是表現第二好的細分市場，這反映了其利用人體自體免疫系統攻擊癌症的潛力。伴隨診斷也日益受到關注，它有助於根據個別基因譜選擇合適的治療方法。人工智慧（AI）和機器學習在精準醫療中的應用進一步提升了預測分析和治療效果。製藥公司與研究機構之間的策略聯盟和合作研究正在加速創新並拓展市場潛力。

市場區隔
類型 治療方法和診斷方法
產品 伴隨診斷、生物標記檢測套組和基因組分析工具
服務 遺傳諮詢、檢測服務和數據解讀服務
科技 次世代定序、聚合酵素鏈鎖反應、原位雜合反應、免疫組織化學、液態生物檢體
適應症 乳癌、肺癌、結腸癌、攝護腺癌
最終用戶 醫院、診斷檢查室、研究機構、製藥公司
成分 軟體、硬體
實施表格 本機部署、雲端部署
解決方案 臨床決策支援、數據管理和預測分析
步 早期診斷，晚期治療

在腫瘤精準醫療市場，主要企業正透過策略定價和創新產品推出不斷擴大市場佔有率。豐富的新型治療方法和診斷工具研發管線正在推動市場競爭，並改善治療效果。各公司專注於根據特定基因譜客製化個人化解決方案，以最佳化患者預後。這種充滿活力的市場環境促進了合作與夥伴關係的建立，而合作與夥伴關係對於加速研發至關重要。競爭基準研究揭示了高度競爭的市場環境，主要參與者正透過策略聯盟和併購來爭奪主導。監管影響發揮關鍵作用，嚴格的指導方針塑造著產品開發和打入市場策略。監管核准的增加促進了最先進治療的應用。隨著技術進步和人工智慧的融合革新患者照護，競爭格局進一步加劇。隨著市場的發展，相關人員必須應對複雜的監管環境，並利用技術創新來保持競爭優勢。

主要趨勢和促進因素：

腫瘤精準醫療市場正經歷強勁成長，這主要得益於基因組技術和個人化治療方法的進步。其中一個關鍵趨勢是將人工智慧 (AI) 和機器學習應用於數據分析，從而提高癌症診斷和治療方案製定的準確性。這些技術能夠識別新的生物標記和治療靶點，促進個人化醫療的有效性和廣泛應用。另一個重要趨勢是製藥公司與研究機構之間合作的加強。這種協同作用正在加速藥物研發進程，並開發出針對個體基因譜的創新治療方法。癌症發病率的上升和對標靶治療解決方案的核准流程，以加速其市場准入。新興市場擁有不斷完善的醫療基礎設施和日益增強的精準醫療意識，蘊藏著許多機會。投資研發並建立策略聯盟的公司能夠更好地利用這些趨勢，推動市場成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 治療方法
    • 診斷
  • 市場規模及預測：依產品分類
    • 伴隨診斷
    • 生物標記檢測套組
    • 基因組分析工具
  • 市場規模及預測：依服務分類
    • 遺傳諮詢
    • 檢查服務
    • 數據解讀服務
  • 市場規模及預測：依技術分類
    • 次世代定序
    • 聚合酵素鏈鎖反應
    • 原位雜合反應
    • 免疫組織化學
    • 液態生物檢體
  • 市場規模及預測：依應用領域分類
    • 乳癌
    • 肺癌
    • 大腸直腸癌
    • 攝護腺癌
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷檢查室
    • 研究所
    • 製藥公司
  • 市場規模及預測：依組件分類
    • 軟體
    • 硬體
  • 市場規模及預測：依發展狀況
    • 本地部署
    • 基於雲端的
  • 市場規模及預測：按解決方案分類
    • 臨床決策支持
    • 資料管理
    • 預測分析
  • 市場規模及預測：依疾病階段分類
    • 早期診斷
    • 晚期治療

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Foundation Medicine
  • Guardant Health
  • Caris Life Sciences
  • Tempus
  • Natera
  • Neo Genomics
  • Personalis
  • Adaptive Biotechnologies
  • Freenome
  • GRAIL
  • Oncocyte Corporation
  • Invitae
  • Biodesix
  • Strata Oncology
  • Exact Sciences
  • Illumina
  • Blueprint Medicines
  • Loxo Oncology
  • Myriad Genetics
  • Molecular MD

第9章：關於我們

簡介目錄
Product Code: GIS31514

Oncology Precision Medicine Market is anticipated to expand from $61.3 billion in 2024 to $159.1 billion by 2034, growing at a CAGR of approximately 9.4%. The Oncology Precision Medicine Market encompasses targeted therapies and diagnostics tailored to individual genetic profiles, enhancing treatment efficacy and reducing adverse effects. This market is driven by advances in genomics, bioinformatics, and personalized healthcare, enabling precise identification of cancer mutations. Increasing cancer prevalence and demand for personalized treatment are propelling growth, encouraging innovations in biomarker discovery and companion diagnostics.

The Oncology Precision Medicine Market is experiencing robust growth, driven by advancements in personalized treatment approaches and molecular diagnostics. The diagnostics segment leads in performance, with next-generation sequencing and liquid biopsy technologies being pivotal in early and accurate cancer detection. Among these, next-generation sequencing stands out due to its comprehensive genomic profiling capabilities. The therapeutics segment follows closely, with targeted therapies and immunotherapies revolutionizing cancer treatment paradigms. Within therapeutics, targeted therapies are the top-performing sub-segment, offering personalized treatment options that improve patient outcomes. Immunotherapies are the second highest-performing sub-segment, reflecting their potential in harnessing the body's immune system to combat cancer. Companion diagnostics are gaining traction, facilitating the selection of appropriate therapies based on individual genetic profiles. The integration of artificial intelligence and machine learning in precision medicine is further enhancing predictive analytics and treatment efficacy. Strategic partnerships and collaborations among pharmaceutical companies and research institutions are accelerating innovation and expanding the market's potential.

Market Segmentation
TypeTherapies, Diagnostics
ProductCompanion Diagnostics, Biomarker Testing Kits, Genomic Profiling Tools
ServicesGenetic Counseling, Laboratory Services, Data Interpretation Services
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Immunohistochemistry, Liquid Biopsy
ApplicationBreast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
End UserHospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies
ComponentSoftware, Hardware
DeploymentOn-premise, Cloud-based
SolutionsClinical Decision Support, Data Management, Predictive Analytics
StageEarly-stage Diagnosis, Advanced-stage Treatment

In the Oncology Precision Medicine Market, leading companies are expanding their market share through strategic pricing and innovative product launches. The landscape is characterized by a robust pipeline of novel therapies and diagnostic tools, driving competition and enhancing treatment efficacy. Companies are focusing on personalized solutions that address specific genetic profiles, thus optimizing patient outcomes. This dynamic environment is fostering collaborations and partnerships, which are pivotal in accelerating research and development efforts. Competition benchmarking reveals a highly competitive arena with key players vying for dominance through strategic alliances and mergers. Regulatory influences play a significant role, with stringent guidelines shaping product development and market entry strategies. The market is witnessing increased regulatory approvals, facilitating the introduction of cutting-edge therapies. The competitive landscape is further intensified by technological advancements and the integration of artificial intelligence, which are revolutionizing patient care. As the market evolves, stakeholders must navigate regulatory complexities and leverage technological innovations to maintain a competitive edge.

Geographical Overview:

The Oncology Precision Medicine Market is witnessing substantial growth across various regions, each with unique dynamics. North America leads, fueled by advanced healthcare infrastructure and significant investments in personalized medicine. The presence of major biotech firms and cutting-edge research institutions further propels the market's expansion. Europe follows closely, with strong governmental support for precision medicine initiatives and a robust regulatory framework that promotes innovation. Asia Pacific is emerging as a key growth pocket, driven by increasing healthcare expenditure and the rising prevalence of cancer. Countries like China and India are investing heavily in precision medicine research, fostering a conducive environment for market growth. Latin America and the Middle East & Africa are also showing promising potential. Brazil and Mexico are notable for their expanding healthcare sectors, while the Middle East & Africa are recognizing the importance of precision medicine in addressing regional health challenges and improving patient outcomes.

Global tariffs and geopolitical tensions are significantly impacting the Oncology Precision Medicine Market, particularly in East Asia. Japan and South Korea are navigating trade barriers by enhancing domestic R&D in precision oncology, aiming to reduce dependency on foreign technologies. China's strategy focuses on fostering indigenous innovation amidst export restrictions, while Taiwan continues to leverage its semiconductor prowess, albeit with heightened geopolitical risks. The parent market is witnessing robust growth driven by advancements in genomics and personalized therapies, yet is vulnerable to supply chain disruptions. By 2035, the market is anticipated to evolve with increased regional collaborations and technological self-reliance. Middle East conflicts exacerbate these challenges by influencing energy prices, thereby affecting manufacturing and logistics costs globally.

Key Trends and Drivers:

The Oncology Precision Medicine Market is experiencing robust expansion, fueled by advancements in genomic technologies and personalized treatment approaches. A key trend is the integration of artificial intelligence and machine learning in data analysis, enhancing the accuracy of cancer diagnosis and treatment plans. These technologies enable the identification of novel biomarkers and therapeutic targets, driving personalized medicine's effectiveness and adoption. Another significant trend is the growing collaboration between pharmaceutical companies and research institutions. This synergy accelerates drug discovery and development processes, resulting in innovative therapies tailored to individual genetic profiles. The increasing prevalence of cancer and the demand for targeted therapies further propel market growth. Precision medicine reduces adverse effects and improves patient outcomes, making it an attractive option for healthcare providers. Moreover, government initiatives and funding for cancer research are creating a conducive environment for market development. Regulatory bodies are streamlining approval processes for precision medicine solutions, facilitating faster market entry. Opportunities abound in emerging markets where healthcare infrastructure is evolving, and awareness of precision medicine is rising. Companies that invest in research and development, while forming strategic partnerships, are well-positioned to capitalize on these trends and drive market growth.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Therapies
    • 4.1.2 Diagnostics
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Companion Diagnostics
    • 4.2.2 Biomarker Testing Kits
    • 4.2.3 Genomic Profiling Tools
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genetic Counseling
    • 4.3.2 Laboratory Services
    • 4.3.3 Data Interpretation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 In Situ Hybridization
    • 4.4.4 Immunohistochemistry
    • 4.4.5 Liquid Biopsy
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Breast Cancer
    • 4.5.2 Lung Cancer
    • 4.5.3 Colorectal Cancer
    • 4.5.4 Prostate Cancer
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Software
    • 4.7.2 Hardware
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 On-premise
    • 4.8.2 Cloud-based
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Clinical Decision Support
    • 4.9.2 Data Management
    • 4.9.3 Predictive Analytics
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Early-stage Diagnosis
    • 4.10.2 Advanced-stage Treatment

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Deployment
      • 5.2.1.9 Solutions
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Deployment
      • 5.2.2.9 Solutions
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Deployment
      • 5.2.3.9 Solutions
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Deployment
      • 5.3.1.9 Solutions
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Deployment
      • 5.3.2.9 Solutions
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Deployment
      • 5.3.3.9 Solutions
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Deployment
      • 5.4.1.9 Solutions
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Deployment
      • 5.4.2.9 Solutions
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Deployment
      • 5.4.3.9 Solutions
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Deployment
      • 5.4.4.9 Solutions
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Deployment
      • 5.4.5.9 Solutions
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Deployment
      • 5.4.6.9 Solutions
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Deployment
      • 5.4.7.9 Solutions
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Deployment
      • 5.5.1.9 Solutions
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Deployment
      • 5.5.2.9 Solutions
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Deployment
      • 5.5.3.9 Solutions
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Deployment
      • 5.5.4.9 Solutions
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Deployment
      • 5.5.5.9 Solutions
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Deployment
      • 5.5.6.9 Solutions
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Deployment
      • 5.6.1.9 Solutions
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Deployment
      • 5.6.2.9 Solutions
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Deployment
      • 5.6.3.9 Solutions
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Deployment
      • 5.6.4.9 Solutions
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Deployment
      • 5.6.5.9 Solutions
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Foundation Medicine
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Guardant Health
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Caris Life Sciences
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Tempus
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Natera
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Neo Genomics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Personalis
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Adaptive Biotechnologies
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Freenome
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 GRAIL
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Oncocyte Corporation
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Invitae
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Biodesix
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Strata Oncology
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Exact Sciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Illumina
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Blueprint Medicines
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Loxo Oncology
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Myriad Genetics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Molecular MD
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us